Evidence map›Paper›PMID 41049875›Full record

ArticleCancer informatics2025

Systematic Analysis of CA9 as a Pan-Cancer Marker for Prognosis and Immunity.

Qiang Yi, Yaoyao Mei, Zhu Yang, Yi Liu

Abstract read
In one paragraph

Article in Cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qiang YiChongqing Medical University, P. R. China.
Yaoyao MeiChongqing Medical University, P. R. China.
Zhu YangDepartment of Gynecology and Obstetrics, The Second Affiliated Hospital of Chongqing Medical University, P. R. China.
Yi LiuDepartment of Gynecology and Obstetrics, The Second Affiliated Hospital of Chongqing Medical University, P. R. China.ORCID https://orcid.org/0009-0009-1151-4297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carbonic anhydrase 9 (CA9) plays a crucial role in pH regulation and adaptation under hypoxic conditions in the tumor microenvironment. Despite its known involvement in the progression of specific cancers, a comprehensive pan-cancer examination of the prognostic value and biological implications of CA9 has not been performed. This study systematically explored the diverse roles of CA9 across multiple cancer types. Methods: Bioinformatics methods were applied via extensive datasets from TCGA, GTEx, CPTAC, CancerSEA, and the public literature. We systematically analyzed the associations between CA9 expression profiles and various clinical parameters, prognosis, immune infiltration, immune-related genes, TMB, MSI, and tumor stemness scores. Additionally, a single-cell functional analysis was conducted. Results: CA9 was significantly upregulated in 29 out of 33 cancer types, indicating high discriminatory ability between tumor and normal tissues. Elevated CA9 expression correlated with poor OS and PFIs in multiple cancers, such as GBMLGG, CESC, LUAD, KIPAN, GBM, THYM, LIHC, THCA, PAAD, and KICH. In 39 cancers, CA9 expression was predominantly negatively correlated with the infiltration of 22 immune cell infiltrations. It was also associated with TMB in 12 tumors and with MSI in 9. Single-cell analysis revealed positive links between CA9 and essential processes such as hypoxia, metastasis, angiogenesis, and stemness. Conclusion: This study provides compelling evidence that CA9 is a potential pan-cancer prognostic marker and diagnostic tool. The associations of CA9 with immune components and determinants of immunotherapy response indicate the importance of CA9 in advancing cancer research and personalized treatment strategies.

Indexed as

biomarkerCA9immune infiltrationpan-cancerprognosis

Identifiers

PMID41049875
PMCPMC12489208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.